Nordic Nanovector ASA: Extraordinary General Meeting held

Thu, Dec 01, 2022 12:23 CET

Oslo, Norway, 1 December 2022

An Extraordinary General Meeting (the "EGM") of Nordic Nanovector ASA (the "Company") (OSE: NANOV) was held today on 1 December 2022 in Oslo, Norway.

The matters under item 3, the proposed transaction with APIM Therapeutics AS, did not obtain sufficient majority of votes and was thus voted down. Due to the results under item 3, the EGM did not vote for the matters under item 4, 5, 6 and 7. The complete minutes of the EGM are attached to this release, and are available on www.nordicnanovector.com.

For further information, please contact:

IR enquiries

Malene Brondberg, interim CEO and CFO

Cell: +44 7561 431 762

Email: ir@nordicnanovector.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)

Tel: +44 203 928 6900

Email: nordicnanovector@medistrava.com

This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

Tags:

Cancer Therapy non-hodgkins lymphoma Betalutin Nordic Nanovector Radioimmunotherapy Roy Hartvig Larsen anticancer therapeutics